Literature DB >> 17869524

The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen.

Lisa Y Wu1, Marc O Anderson, Yoko Toriyabe, Jack Maung, Tammy Y Campbell, Cheryl Tajon, Marat Kazak, Jamie Moser, Clifford E Berkman.   

Abstract

To identify the pharmacophore of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen (PSMA), a small analog library was designed and screened for inhibitory potency against PSMA. The design of the lead inhibitor was based upon N-acyl derivatives of endogenous substrate folyl-gamma-Glu and incorporates a phosphoramidate group to interact with the PSMA catalytic zinc atoms. The scope of the analog library was designed to test the importance of various functional groups to the inhibitory potency of the lead phosphoramidate. The IC(50) for the lead phosphoramidate inhibitor was 35 nM while the IC(50) values for the analog library presented a range from 0.86 nM to 4.1 microM. Computational docking, utilizing a recently solved X-ray crystal structure of the recombinant protein, along with enzyme inhibition data, was used to propose a pharmacophore model for the PSMA active site.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869524      PMCID: PMC2065856          DOI: 10.1016/j.bmc.2007.07.028

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  22 in total

1.  Synthesis of 1233A analogs and their inhibitory activity against hydroxymethylglutaryl coenzyme A synthase.

Authors:  T Sunazuka; K Tsuzuki; H Kumagai; H Tomoda; H Tanaka; H Nagashima; H Hashizume; S Omura
Journal:  J Antibiot (Tokyo)       Date:  1992-07       Impact factor: 2.649

Review 2.  A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy?

Authors:  J Tasch; M Gong; M Sadelain; W D Heston
Journal:  Crit Rev Immunol       Date:  2001       Impact factor: 2.214

3.  Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography.

Authors:  Tiancheng Liu; Yoko Toriyabe; Clifford E Berkman
Journal:  Protein Expr Purif       Date:  2006-05-22       Impact factor: 1.650

4.  Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.

Authors:  S S Chang; V E Reuter; W D Heston; P B Gaudin
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

5.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature.

Authors:  S S Chang; D S O'Keefe; D J Bacich; V E Reuter; W D Heston; P B Gaudin
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

6.  Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.

Authors:  Jun Lu; Esteban Celis
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

Review 7.  Ins and outs of clinical trials with peptide-based vaccines.

Authors:  Rachel B Salit; W Martin Kast; Markwin P Velders
Journal:  Front Biosci       Date:  2002-05-01

8.  Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates.

Authors:  Jack Maung; Jeremy P Mallari; Teri A Girtsman; Lisa Y Wu; Jennifer A Rowley; Nicholas M Santiago; Alan N Brunelle; Clifford E Berkman
Journal:  Bioorg Med Chem       Date:  2004-09-15       Impact factor: 3.641

9.  LNCaP model of human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; E Kawinski; J P Karr; H Rosenthal; T M Chu; E A Mirand; G P Murphy
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

10.  Anti-tumor effects of toxins targeted to the prostate specific membrane antigen.

Authors:  Giulio Fracasso; Giuseppe Bellisola; Sara Cingarlini; Deborah Castelletti; Tommaso Prayer-Galetti; Francesco Pagano; Giuseppe Tridente; Marco Colombatti
Journal:  Prostate       Date:  2002-09-15       Impact factor: 4.104

View more
  20 in total

1.  Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2011-10-04       Impact factor: 2.823

2.  Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.

Authors:  Lisa Y Wu; Jacqueline M Johnson; Jessica K Simmons; Desiree E Mendes; Jonathan J Geruntho; Tiancheng Liu; Wessel P Dirksen; Thomas J Rosol; William C Davis; Clifford E Berkman
Journal:  Prostate       Date:  2014-01-21       Impact factor: 4.104

3.  Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Lisa Y Wu; Jeonghoon Lee; Peter T A Reilly; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

4.  Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.

Authors:  Benjamin B Kasten; Tiancheng Liu; Jessie R Nedrow-Byers; Paul D Benny; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2012-11-16       Impact factor: 2.823

Review 5.  Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer.

Authors:  Sagnik Sengupta; Mena Asha Krishnan; Sudeshna Chattopadhyay; Venkatesh Chelvam
Journal:  Cancer Rep (Hoboken)       Date:  2019-04-02

6.  N-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2).

Authors:  Brian R Blank; Pinar Alayoglu; William Engen; Joseph K Choi; Clifford E Berkman; Marc O Anderson
Journal:  Chem Biol Drug Des       Date:  2011-02-22       Impact factor: 2.817

7.  In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.

Authors:  Tiancheng Liu; Lisa Y Wu; Joseph K Choi; Clifford E Berkman
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

8.  Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.

Authors:  Lisa Y Wu; Jacinda C Do; Marat Kazak; Helen Page; Yoko Toriyabe; Marc O Anderson; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2007-10-30       Impact factor: 2.823

9.  PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

Authors:  Jessie R Nedrow-Byers; Adam L Moore; Tanushree Ganguly; Mark R Hopkins; Melody D Fulton; Paul D Benny; Clifford E Berkman
Journal:  Prostate       Date:  2012-08-21       Impact factor: 4.104

10.  Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.

Authors:  Shorouk Dannoon; Tanushree Ganguly; Hendry Cahaya; Jonathan J Geruntho; Matthew S Galliher; Sophia K Beyer; Cindy J Choy; Mark R Hopkins; Melanie Regan; Joseph E Blecha; Lubica Skultetyova; Christopher R Drake; Salma Jivan; Cyril Barinka; Ella F Jones; Clifford E Berkman; Henry F VanBrocklin
Journal:  J Med Chem       Date:  2016-06-13       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.